With the increasing aging of population in China, the country has also opened the policy of two children. However, although the policy has brought good conditions to many families, there are also many problems.

After the implementation of the comprehensive two child policy, the cumulative demand for birth was released. In 2016, there were 17.86 million newborns in China, with the birth rate increasing by more than 15%. At the same time, the proportion of elderly mothers increased, and the premature rate increased by nearly 10%.

It can be said that with the release of the second child, the increase of maternal age and the rapid development of assisted reproductive technology, the risk of premature birth is increasing. Therefore, the World Health Organization has designated November 17 as the world premature birth day, calling for people to pay attention to premature babies.

In China, the average incidence of preterm birth is 7%, while that of assisted reproduction is 15% - 20%. The incidence of twin or multiple preterm birth is more than 50%. Premature infants will have various complications because of congenital deficiency, and the cost of treatment is high. Mothers and families not only have to pay a huge economic and spiritual cost. More importantly, it is related to the health problems of premature infants. Now experts at home and abroad are also increasing the research on drugs for the treatment of premature birth.

The development of these drugs not only makes the curative effect of the drugs more excellent, safer and ideal, but also witnesses the contribution of the development of medical treatment field to human health. It is also the progress of medicine and human beings to let those patients who are deeply ill recover as soon as possible.

Xinnoan @ atoxicban acetate injection, a drug produced by Chengdu shengnuo biopharmaceutical Co., Ltd., is used to delay the coming of premature delivery.

As the first peptide oxytocin receptor antagonist in the world, atoxicam acetate injection is the most excellent drug against premature delivery, with reliable efficacy and high safety. The emergence of the drug represents that it can prolong the gestational weeks for the patients with preterm delivery from 24 to 33 weeks, improve the survival rate of preterm infants and reduce the complications of newborns.

Premature delivery is a common concern of the whole world, and has a high incidence rate. Uterine contraction is one of the main symptoms of labor, which needs to be restrained to prevent immediate premature delivery, so as to gain time for the completion of fetal lung therapy and transfer of pregnant women to the hospital where there are conditions for the rescue of premature infants.

Atoxicam acetate is a special product for the national "11th Five Year Plan" major new drug development. It has obtained the new drug certificate h20170003, and has been listed as the first-line choice for the treatment of preterm birth by many authoritative global guidelines (eapm, RCOG 2011, 2014, etc.).

Atoxicam acetate injection is a new type of oxytocin receptor antagonist, which can effectively inhibit uterine contraction, and is used to treat pregnant women with preterm birth indication, so as to delay the coming preterm birth. It has strong specificity, low incidence of adverse reactions, rapid inhibition of uterine contraction and effective prolongation of gestational weeks, accuracy, flexibility, high efficiency and safety. It is safe, powerful and precise.

According to the HDM system of CFDA South Institute of medicine and economics, the sales volume of atoxicam acetate increased by 88% year on year in 2016. With the overall liberalization of the two child policy, atoxicam acetate.

Shengnuo bio PRODUCT

Best sales manager contact

About Shengnuo

Chengdu Shengnuo Biotechnology Co., Ltd. has "Chengdu polypeptide drug engineering technology research center" in Chengdu, mainly engaged in polypeptide, polypeptide drug and beauty peptide research. Our zero defect has passed the FDA certification, and now it has become the first-class professional peptide drug and product development, technology transfer, technical service and peptide drug industry in the scale production and export of China's parks.